Publication: A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection
Issued Date
2019-10-01
Resource Type
ISSN
15292916
15292908
15292908
Other identifier(s)
2-s2.0-85071686228
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Nature Immunology. Vol.20, No.10 (2019), 1291-1298
Suggested Citation
Jose Luis Slon-Campos, Wanwisa Dejnirattisai, Brett W. Jagger, César López-Camacho, Wiyada Wongwiwat, Lorellin A. Durnell, Emma S. Winkler, Rita E. Chen, Arturo Reyes-Sandoval, Felix A. Rey, Michael S. Diamond, Juthathip Mongkolsapaya, Gavin R. Screaton A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. Nature Immunology. Vol.20, No.10 (2019), 1291-1298. doi:10.1038/s41590-019-0477-z Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/51015
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection
Other Contributor(s)
Western Michigan University Homer Stryker M.D. School of Medicine
University of Oxford
Washington University School of Medicine in St. Louis
Faculty of Medicine, Siriraj Hospital, Mahidol University
Nuffield Department of Clinical Medicine
CNRS Centre National de la Recherche Scientifique
Institut Pasteur, Paris
University of Oxford
Washington University School of Medicine in St. Louis
Faculty of Medicine, Siriraj Hospital, Mahidol University
Nuffield Department of Clinical Medicine
CNRS Centre National de la Recherche Scientifique
Institut Pasteur, Paris
Abstract
© 2019, The Author(s), under exclusive licence to Springer Nature America, Inc. Infections with dengue virus (DENV) and Zika virus (ZIKV) can induce cross-reactive antibody responses. Two immunodominant epitopes—one to precursor membrane protein and one to the fusion loop epitope on envelope (E) protein—are recognized by cross-reactive antibodies1–3 that are not only poorly neutralizing, but can also promote increased viral replication and disease severity via Fcγ receptor-mediated infection of myeloid cells—a process termed antibody-dependent enhancement (ADE)1,4,5. ADE is a significant concern for both ZIKV and DENV vaccines as the induction of poorly neutralizing cross-reactive antibodies may prime an individual for ADE on natural infection. In this report, we describe the design and production of covalently stabilized ZIKV E dimers, which lack precursor membrane protein and do not expose the immunodominant fusion loop epitope. Immunization of mice with ZIKV E dimers induces dimer-specific antibodies, which protect against ZIKV challenge during pregnancy. Importantly, the ZIKV E-dimer-induced response does not cross-react with DENV or induce ADE of DENV infection.